Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib - the role of extracellular signal-regulated kinase counteraction

A dual role of p53 in the control of autophagy

(2014) Ezgi Tasdemir et al.   Autophagy

Doxorubicin and sorafenib improves survival in patients with advanced hepatocellular carcinoma

(2011) Lisa Hutchinson   Nature Reviews Clinical Oncology

Targeting the pro-death and pro-survival functions of autophagy as novel therapeutic strategies in cancer

(2010) Kevin Dalby et al.   Autophagy

Regulation of DNA fragmentation: the role of caspases and phosphorylation

(2010) Ikuko Kitazumi et al.   FEBS Journal

Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo

(2010) Gang Wei et al.   INTERNATIONAL JOURNAL OF CANCER

Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma

(2010) Ghassan K. Abou-Alfa et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Differences in Effects on Myocardium and Mitochondria by Angiogenic Inhibitors Suggest Separate Mechanisms of Cardiotoxicity

(2010) Kevin J. French et al.   TOXICOLOGIC PATHOLOGY

Targeting the RAF–MEK–ERK pathway in cancer therapy

(2009) Clara Montagut et al.   CANCER LETTERS

ERK and cell death: Mechanisms of ERK-induced cell death - apoptosis, autophagy and senescence

(2009) Sebastien Cagnol et al.   FEBS Journal

Apoptosis and autophagy: Targeting autophagy signalling in cancer cells -‘trick or treats’?

(2009) Elisabeth A. Corcelle et al.   FEBS Journal

Transcription Factor GATA4 Inhibits Doxorubicin-induced Autophagy and Cardiomyocyte Death

(2009) Satoru Kobayashi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Resistance to Mitogen-Activated Protein Kinase Kinase (MEK) Inhibitors Correlates with Up-Regulation of the MEK/Extracellular Signal-Regulated Kinase Pathway in Hepatocellular Carcinoma Cells

(2009) M. T. Yip-Schneider et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Multimodal approaches to the treatment of hepatocellular carcinoma

(2009) Giuseppe Cabibbo et al.   Nature Reviews Gastroenterology & Hepatology

Dysregulation of apoptosis in hepatocellular carcinoma cells

(2009) Isabel Fabregat   WORLD JOURNAL OF GASTROENTEROLOGY

ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes

(2008) Jiahao Liu et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Tumour cell survival signalling by the ERK1/2 pathway

(2008) K Balmanno et al.   CELL DEATH AND DIFFERENTIATION

Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: Results from a phase I extension trial

(2008) H. Richly et al.   EUROPEAN JOURNAL OF CANCER

Inhibition of ERK attenuates autophagy and potentiates tumour necrosis factor-α-induced cell death in MCF-7 cells

(2008) U. Sivaprasad et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Novel advancements in the management of hepatocellular carcinoma in 2008

(2008) Josep M. Llovet et al.   JOURNAL OF HEPATOLOGY

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

(2008) Scott M. Wilhelm et al.   MOLECULAR CANCER THERAPEUTICS

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE